Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Bright Minds Biosciences Inc. - common stock (NQ: DRUG ) 1.220 +0.020 (+1.67%) Streaming Delayed Price Updated: 12:43 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Bright Minds Biosciences Inc. - common stock < Previous 1 2 3 4 Next > Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th September 19, 2024 From Bright Minds Biosciences Via GlobeNewswire Bright Minds Biosciences Reports Improved Financial Position For Q3 Amid Ongoing R&D Efforts August 16, 2024 Bright Minds Biosciences reports a significant reduction in net losses for Q3 2024 while advancing its R&D programs focused on serotonergic therapies for CNS disorders. Via Benzinga DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q3 2024 August 15, 2024 Bright Minds Biosciences just reported results for the third quarter of 2024. Via InvestorPlace Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday August 12, 2024 It's time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today! Via InvestorPlace DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q2 2024 May 20, 2024 Bright Minds Biosciences just reported results for the second quarter of 2024. Via InvestorPlace Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More April 17, 2024 Via Benzinga Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence March 29, 2024 Via Benzinga Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More March 20, 2024 Via Benzinga Topics Economy Exposures Interest Rates Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More March 04, 2024 Via Benzinga Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More February 15, 2024 Via Benzinga Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More February 15, 2024 Via Benzinga Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More January 27, 2024 New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian... Via Benzinga Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More January 12, 2024 Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD Via Benzinga Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More January 07, 2024 Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury Via Benzinga Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More December 27, 2023 President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also... Via Benzinga Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More December 18, 2023 Biden To Decide On Psychedelic Therapy Bill Via Benzinga Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More December 11, 2023 John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy Via Benzinga Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More December 05, 2023 Defense Dept. Funds Ketamine Study For PTSD Treatment Via Benzinga Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More November 24, 2023 GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan Via Benzinga Topics Cannabis Exposures Cannabis Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More November 12, 2023 Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans? Via Benzinga Topics Initial Public Offering Exposures Securities Market Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More November 06, 2023 DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court Via Benzinga Topics Economy Exposures Interest Rates Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More October 29, 2023 Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted Via Benzinga Topics Intellectual Property Exposures Intellectual Property Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted October 22, 2023 Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts Via Benzinga Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More October 16, 2023 Cybin And Small Pharma Shareholders Green Light Acquisition Resolution Via Benzinga Exposures Product Safety Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More October 06, 2023 Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares Via Benzinga Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More October 02, 2023 Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of... Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday September 28, 2023 We're checking out the biggest pre-market stock movers worth watching on Friday with a dive into all of the latest market stories! Via InvestorPlace Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More September 26, 2023 Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge Via Benzinga Topics Economy Exposures Interest Rates Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More September 18, 2023 Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next Via Benzinga Exposures Product Safety Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More September 11, 2023 Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.